
The Science 37 Operating System™



Any Patient. Any Provider. Anywhere.



The traditional clinical trial model hasn't changed in 60+ years.

Disjointed processes, disassociated technologies, and redundant oversight at multiple investigational sites lead to high costs and declining performance. On average, only 3% of physicians¹ and 8% of patients participate in clinical research², with 70% of patients citing that they live 2+ hours away from sites.³

Science 37's Operating System (OS) enables faster trial execution by improving enrollment, retention, and representation with end-to-end trial management that enables greater compliance—delivering high-quality data in complex clinical trials. Configurable to conduct a traditional at-site clinical trial, act as a virtual site (known as a Metasite $^{\text{TM}}$) or deployed in combination with any existing site staff or centralized network, the Science 37 OS enables flexibility across nearly any study design.

The Operating System supports any phase of a study—including pivotal trials or real-world evidence (RWE) studies—for any number of indications such as oncology, CNS, endocrinology, pediatrics, infectious, rare disease, and more. It empowers Sponsors and Contract Resource Organizations (CROs), delivering up to:

15x


Faster Trial Enrollment


28%

Greater Patient Retention


3X

More Diverse Patient Populations





Leveraging unified technology, standardized processes, and centralized networks to accelerate breakthrough clinical research—Science 37's Operating System is capable of reaching patients, providers, and sponsors globally, with direct data capture capabilities and access. The Operating System supports continuity in both decentralized and traditional clinical trials.



Unified Technology Enables a Seamless Experience for All Users and Participants.

Science 37 delivers a global, scalable, and configurable end-to-end platform enabling Agile Clinical Trials—at-site, decentralized, and the full spectrum of hybrid designs. Through the configuration of our unified platform—either by our expert staff or your own organization—sponsors and CROs are able to engage and ultimately retain stakeholders in the study. The Science 37 platform enables:



Workflow Orchestration-

delivers better compliance and decreased cycle times through automation of the workflow in a manner that is simple and intuitive—while meeting the needs of each study persona.



Evidence Generation—

is enabled through eCOA, eSource, and other tools in the unified Science 37 platform or through integration with 3rd party apps, devices, and/or other diagnostic equipment.



Data Harmonization—

ensures that Sponsors and CROs have access to all data generated during the clinical trial, including but not limited to: incorporation of data from outside sources (e.g., EMR/EHR), interoperability with 3rd party evidence providers, and integrations with downstream systems such as EDC, CTMS, and TMF.



Standardized Processes Ensure Compliance and High-quality Data.

Standardized processes drive high-quality data. Our remote coordinators, mobile nurses, and telemedicine investigators, all operate on a standardized set of processes across the Operating System to ensure the experience is the same for each participant. Trial outcomes and patient experience improve with a single process at each touchpoint.

Centralized Networks Provide Extensive Reach.

Quality providers work seamlessly with Science 37's technology platform to help operationalize, conduct, and support increasingly complex agile clinical trial designs both at-home or on-site within local communities.



Patient Communities

Accelerate your trial with multi-channel patient access, including Science 37's registry of 500k+ patients. Attract, enroll and retain more participants beyond the traditional site delivering real-world representation.

Telemedicine Investigators

Source telemedicine investigators on-demand across multiple therapy areas and geographies—enabling patient access from virtually anywhere.

Community Providers

Onboard diverse, trusted community providers to coordinate and collect data with confidence, in support of patient choice for study delivery, enabling continuity of care while expanding reach.

Mobile Nursing


Trusted mobile nurses, phlebotomists, and healthcare providers use Science 37's technology and standardized processes to complete procedures and data collection at-home or on-site—according to patient needs.

Remote Coordinators

Trained coordinators consult, orchestrate, and support patient and study teams by leveraging in-depth experience and standardized processes.

Data & Devices

All data is captured directly in the system, eliminating manual re-entry and providing real-time access into the progress of the trial at any given moment.



95+

45+

Languages

530k+

125+
Clinical Trials
(from 2020 to 2021)

81%Repeat Customers

39% 67%

BIPOC Female Patients

Science 37 accelerates health innovation for all by providing convenient, equitable clinical trial opportunities to patients worldwide. Reach patients and providers outside of existing site networks, activating a diverse patient population. Mitigate risk, ensure business continuity, while leveraging the speed and agility of a virtual site start-up.





Science 37 Representation:
Any Patient, Any Provider, Anywhere.

Our data-driven, multi-channel approach to digital marketing makes it easier to find, enroll, learn from, and retain **more representative**, **real-world patient populations** for global clinical research.

We develop partnerships with those who share our vision of eliminating health disparities, including **community outreach programs**, **global healthcare providers**, **professional networks**, **research organizations**, and **patient advocacy groups**.

SCIENCE 37

Offerings Customizable to Your Study



IF YOU NEED...

A Decentralized Trial

Science 37 orchestrates a range of clinical trials. Our unified platform, seamless data capture, mobile nursing, telemedicine investigators and more, enable a spectrum of clinical research—from single remote elements to fully decentralized.

A Hybrid Mix of Decentralized and On-Site

The Agile Clinical Trial is our multi-modal approach to clinical trials, supporting both decentralized and on-site trials—accelerating timelines, expanding reach, and improving diversity.

A Virtual Site to Extend Traditional Site Reach

With the Science 37 Metasite[™], it's easy to add customizable virtual sites to any new or existing clinical trial without increasing infrastructure costs.

Technology to Support the End-to-End Trial

The Science 37 Technology Platform can be configured to support patient engagement, remote eConsent, eSource (eCOA, eCRF), Telemedicine, and/or third-party devices, integrating with broader trial solutions for sponsors or CROs.



LET'S TALK

Accelerate your clinical research with the agile trial pioneers.

sales@science37.com | science37.com

About Science 37

Science 37, Inc.'s (Nasdaq: SNCE) mission is to enable universal access to clinical research, making it easier for patients and providers to participate from anywhere. Since 2014, we've pioneered decentralized and agile clinical trial approaches and having conducted more than 125 agile clinical trials, we're helping forge the future of research. The Science 37 Operating System (OS) supports today's more agile clinical research design, enabling up to 15x faster enrollment, 28% better retention, and 3x more diverse patient population. To learn more about our solutions, and how we can help you implement Agile and Decentralized Trials, visit www.science37.com, or email science37@science37.com.

¹⁾ Article from JNCI: Journal of the National Cancer Institute, Volume 111, Issue 3, March 2019 - Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, Physician and Patient Barriers to Cancer Clinical Trial Participation: Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. https://academic.oup.com/jnci/article/111/3/245/5307078?login=false

²⁾ Article from JNCI: Journal of the National Cancer Institute, Volume 111, Issue 3, March 2019 - Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation: Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. https://academic.oup.com/jnci/article/111/3/245/5307078?login=false

 $^{3) \} https://www.mckinsey.com/industries/life-sciences/our-insights/no-place-like-home-stepping-up-the-decentralization-of-clinical-trials$

^{*}Considerations must be taken into account for "Any patient, any provider, anywhere" such as regulatory acceptance and internet/Wi-Fi availability.